2. Search Result
Search Result
Isoforms Recommended: ULK1
Results for "

ULK1

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

2

Natural
Products

4

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS15452
    Ulk1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) ULK Others

    Ulk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ulk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ulk1 Mouse Pre-designed siRNA Set A
    Ulk1 Mouse Pre-designed siRNA Set A
  • HY-143466
    ULK1-IN-2

    		FAK ULK AMPK Apoptosis Autophagy Cancer
    ULK1-IN-2 (compound 3s) is a potent ULK1 inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC50 of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer) [1].
    ULK1-IN-2
  • HY-114490
    ULK-101
    5 Publications Verification

    		 ULK Cancer
    ULK-101 is a potent and selective ULK1 inhibitor, with IC50 values of 1.6 nM and 30 nM for ULK1 and ULK2, respectively. ULK-101 suppresses autophagy and sensitizes cancer cells to nutrient stress [1].
    ULK-101
  • HY-137742
    SBP-7455

    		ULK Autophagy Cancer
    SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research [1].
    SBP-7455
  • HY-101923B
    LYN-1604 dihydrochloride
    3 Publications Verification

    		 ULK Autophagy Apoptosis Cancer
    LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) [1].
    LYN-1604 dihydrochloride
  • HY-RS15451
    ULK1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) ULK Others

    ULK1 Human Pre-designed siRNA Set A contains three designed siRNAs for ULK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ULK1 Human Pre-designed siRNA Set A
    ULK1 Human Pre-designed siRNA Set A
  • HY-RS15453
    Ulk1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ulk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ulk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ulk1 Rat Pre-designed siRNA Set A
    Ulk1 Rat Pre-designed siRNA Set A
  • HY-161850
    ULK1-IN-3

    		ULK Apoptosis PARP Autophagy NF-κB AMPK Akt Reactive Oxygen Species (ROS) Cancer
    ULK1-IN-3 (Compound 8) is a novel chromone-based as a potential inhibitor of ULK1. ULK1-IN-3 inhibits cell cycle, autophagy and induces apoptosis, oxidative stress in colon cancer cell lines [1].
    ULK1-IN-3
  • HY-162100
    MR-2088

    		ULK Autophagy Cancer
    MR-2088 is a selective ULK1/ULK2 inhibitor with pEC50 values of 8.3 and 8.7, respectively. MR-2088 selectively inhibits autophagy through ULK1/2 mediated inhibition [1].
    MR-2088
  • HY-101923A
    LYN-1604 hydrochloride

    		ULK Autophagy Apoptosis Cancer
    LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) [1].
    LYN-1604 hydrochloride
  • HY-101923
    LYN-1604
    3 Publications Verification

    		 ULK Autophagy Apoptosis Cancer
    LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) [1].
    LYN-1604
  • HY-158408
    NZ-66

    		ULK Mitophagy Neurological Disease
    NZ-66 is a UNC-51-like kinase 1 (ULK1) targeting chimera, which is used to achieve proximity-induced and ULK1-dependent degradation of mitochondria. NZ-66 induces mitophagy. NZ-66 is potential for attenuating neurodegenerative disorders [1].
    NZ-66
  • HY-137506
    XST-14
    1 Publications Verification

    		 ULK p38 MAPK TGF-β Receptor Anaplastic lymphoma kinase (ALK) CaMK Apoptosis Cancer
    XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects [1].
    XST-14
  • HY-13018
    MRT67307
    20+ Cited Publications

    		 IKK ULK Autophagy Inflammation/Immunology Cancer
    MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively [1]. MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells .
    MRT67307
  • HY-13018B
    MRT67307 dihydrochloride

    		IKK ULK Autophagy Inflammation/Immunology Cancer
    MRT67307 dihydrochloride is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively [1]. MRT67307 dihydrochloride also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 dihydrochloride also blocks autophagy in cells .
    MRT67307 dihydrochloride
  • HY-13018A
    MRT67307 hydrochloride

    		IKK ULK Autophagy Inflammation/Immunology Cancer
    MRT67307 hydrochloride is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively [1]. MRT67307 hydrochloride also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks autophagy in cells .
    MRT67307 hydrochloride
  • HY-16966
    SBI-0206965
    30+ Cited Publications

    		 ULK AMPK Autophagy Apoptosis Cancer
    SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2. SBI-0206965 is also an AMPK inhibitor that can paradoxically increase Thr172 phosphorylation [1] .
    SBI-0206965
  • HY-168507
    SG31

    		Autophagy Cancer
    SG31 is a potent autophagy activator via the AMPK/ULK1-dependent pathway [1].
    SG31
  • HY-100006
    MRT68921
    20+ Cited Publications

    		 ULK Reactive Oxygen Species (ROS) Apoptosis GSK-3 Bcl-2 Family Cancer
    MRT68921 is a potent NUAK1/ULK1 dual inhibitor. MRT68921 inhibits ULK1 and ULK2 with IC50 values of 2.9 nM and 1.1 nM, respectively. MRT68921 can block cells autophagy and kill tumor cells by breaking the balance of oxidative stress signals. MRT68921 can inhibit cell proliferation and induce ROS production and apoptosis. MRT68921 can be used for the research of cancer, such as breast cancer [1] .
    MRT68921
  • HY-100006B
    MRT68921 hydrochloride

    		ULK Reactive Oxygen Species (ROS) Apoptosis GSK-3 Bcl-2 Family Cancer
    MRT68921 hydrochloride is a potent NUAK1/ULK1 dual inhibitor. MRT68921 hydrochloride inhibits ULK1 and ULK2 with IC50 values of 2.9 nM and 1.1 nM, respectively. MRT68921 hydrochloride can block cells autophagy and kill tumor cells by breaking the balance of oxidative stress signals. MRT68921 hydrochloride can inhibit cell proliferation and induce ROS production and apoptosis. MRT68921 hydrochloride can be used for the research of cancer, such as breast cancer [1] .
    MRT68921 hydrochloride
  • HY-100006A
    MRT68921 dihydrochloride
    20+ Cited Publications

    		 ULK Reactive Oxygen Species (ROS) Apoptosis GSK-3 Bcl-2 Family Cancer
    MRT68921 dihydrochloride is a potent NUAK1/ULK1 dual inhibitor. MRT68921 dihydrochloride inhibits ULK1 and ULK2 with IC50 values of 2.9 nM and 1.1 nM, respectively. MRT68921 dihydrochloride can block cells autophagy and kill tumor cells by breaking the balance of oxidative stress signals. MRT68921 dihydrochloride can inhibit cell proliferation and induce ROS production and apoptosis. MRT68921 dihydrochloride can be used for the research of cancer, such as breast cancer [1] .
    MRT68921 dihydrochloride
  • HY-117413
    SR-17398

    		ULK Cancer
    SR-17398 is an inhibitor for Unc-51-Like Kinase 1 (ULK1) with an IC50 of 22.4 μM [1].
    SR-17398
  • HY-115570
    GW406108X
    1 Publications Verification

    GW108X

    		 Kinesin ULK Autophagy Cancer
    GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK [1] .
    GW406108X
  • HY-N4176
    Ginkgolide K

    		Autophagy Neurological Disease
    Ginkgolide K, isolated from Ginkgo biloba, induces protective autophagy through the AMPK/mTOR/ULK1 signaling pathway. Ginkgolide K possesses neuroprotective activity [1].
    Ginkgolide K
  • HY-119137
    AMDE-1

    		Autophagy AMPK Cancer
    AMDE-1 is a potent autophagy inducer. AMDE-1 induces autophagy by the AMPK-mTORC1-ULK1 pathway and at the same time inhibited autophagy-mediated degradation by causing lysosome dysfunction. AMDE-1 can be used in research of cancer [1].
    AMDE-1
  • HY-N0867
    13-Oxyingenol-13-dodecanoate

    		HIV ULK Bcl-2 Family Infection Cancer
    13-Oxyingenol-dodecanoate (13OD) is a tumor suppressor agent. 13-Oxyingenol-dodecanoate has anti-HIV-1 activity with EC50 value of 33.7 nM [1].13-Oxyingenol-dodecanoate can induce the expression of ULK1 to effect mitochondrial dysfunction and cellular autophagy. 13-Oxyingenol-dodecanoate also increases the expression of BAX and suppresses the expression of BCL-2 to effect apoptosis .
    13-Oxyingenol-13-dodecanoate
  • HY-124729A
    (Rac)-BL-918

    		ULK Autophagy Neurological Disease
    (Rac)-BL-918 is the racemate of BL-918. BL-918 is a potent activator of UNC-51-like kinase 1 (ULK1), inducing cytoprotective autophagy for Parkinson’s disease treatment [1].
    (Rac)-BL-918
  • HY-160699
    DCC-3116

    		ULK Ras Autophagy Cancer
    DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can inhibit autophagy in lung cancer cells by inhibiting KRAS G12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects [1].
    DCC-3116
  • HY-124729
    BL-918
    2 Publications Verification

    		 ULK Autophagy Neurological Disease
    BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment [1].
    BL-918
  • HY-10249
    GSK-690693
    Maximum Cited Publications
    36 Publications Verification

    		 Akt AMPK Autophagy Cancer
    GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation [1] .
    GSK-690693
  • HY-D0195
    Acesulfame potassium

    		PD-1/PD-L1 ERK mTOR Autophagy Neurological Disease Metabolic Disease
    Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion [1] .
    Acesulfame potassium
  • HY-148061
    DB1113

    		PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity [1].
    DB1113
  • HY-148065
    FMF-06-098-1

    		PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK Cancer
    FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 (Pink: target protein ligand (HY-169396); Blue: VHL ligand (HY-112078); Black: Linker (HY-124380)) [1].
    FMF-06-098-1
  • HY-148063
    DB0614

    		PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK Metabolic Disease
    DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity [1] .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))
    DB0614

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: